<DOC>
	<DOCNO>NCT02776527</DOCNO>
	<brief_summary>The main purpose study evaluate whether Apatinib improve disease free survival ( DFS ) gastric cancer patient stage IIIB/IIIc , complete postoprative adjuvant chemotherapy . Meanwhile , investigator also evaluate whether Apatinib improve overall survival ( OS ) , estimate quality life patient take Apatinib monitor security Apatinib .</brief_summary>
	<brief_title>A Clinical Trial Maintenance Treatment Apatinib Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy</brief_title>
	<detailed_description>The investigator recruit 40 gastric cancer patient underwent D2 lymphadenectomy histologically verified stage ⅢB ⅢC accord seventh edition TNM classification gastric cancer . When patient complete 8 cycle Xelox adjuvant chemotherapy without recurrence , randomly assign group A B . Each group possess 20 gastric cancer patient finally . Patients group A receive best supportive care，and take Apatinib 500mg/qd orally , 28 day cycle , till disease progress . Patients group B receive best supportive care . Through follow-up statistic , investigator observe whether Apatinib improve disease free survival ( DFS ) gastric cancer patient stage IIIb &amp; IIIC . Meanwhile , investigator also observe whether Apatinib improve overall survival ( OS ) estimate quality life patient take Apatinib .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Age patient range 18 to75 year old . 2 . Score Eastern Cooperative Oncology Group ( ECOG ) performance status range 0 2 . 3 . All tumor tissue histologically verify advanced gastric cancer , patient le 15 dissected lymph node stage ⅢB ⅢC accord TNM , chosen . 4 . Gastric cancer patient underwent curative gastrectomy D2 lymphadenectomy . 5 . Gastric cancer patient receive postoprative adjuvant chemotherapy eight cycle Xelox . During period chemotherapy , one relapse . If patient could well tolerate adjuvant chemotherapy , recommend patient obtain maintenance treatment Apatinib postoprative adjuvant chemotherapy eight cycle Xelox . 6 . Previously , patient receive therapy Apatinib VEGFR inhibitor , Sorafenib , Sunitinib . 7 . The blood examination normal : neutrophil count≥1.5×109/L；hemoglobin≥80 g/L；blood platelet count≥100×109/L；total bilirubin≤1.5×ULN；ALT、AST≤2.5×ULN； 8 . Patients serious heart , lung , liver , kidney disease jaundice digestive tract obstruction . Patients acute infection . 1 . The score KPS &lt; 60 anticipated survival time＜3 month . 2 . Previously , patient receive neoadjuvant chemotherapy . 3 . Within six month , patient encounter heart cerebral disease , get uncontrolled hypertension ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) , serious coronary heart disease , serious arrhythmia , firstgrade cardiac insufficiency . Patients positive urinary protein . 4 . Patients clear gastrointestinal bleeding tendency , local active ulcer lesion , fecal occult blood ( ++ ) ; Patients symptoms melena haematemesis within 2 month . 5 . Coagulopathy ( INR &gt; 1.5、APTT &gt; 1.5 ULN ) , hemorrhage tendency . 6 . Patients symptom , dysphagia , nausea , vomit , chronic diarrhea intestinal obstruction . 7 . Patients symptom , neurological disease , mental illness , serious infection . 8 . Patients pregnant , nursing , bear requirement study period . 9 . Patients get primary malignant tumor ( except curable skin basal cell carcinoma cervical cancer situ ) except gastric cancer within 5 year . 10 . Patients distant metastasis . 11 . Within 6 month study start process study , patient participate clinical research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>D2 Lymphadenectomy</keyword>
	<keyword>postoprative adjuvant chemotherapy</keyword>
	<keyword>Apatinib</keyword>
	<keyword>disease free survival</keyword>
</DOC>